ArticleInflammopharmacology2026
Modulation of inflammatory and oxidative stress pathways by ethanolic extract of Suaeda fruticosa Forssk. Ex J.F.Gmel in animal models of ulcerative colitis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Chronic inflammation accompanied by oxidative imbalance plays an essential role in the pathogenesis of ulcerative colitis (UC). Suaeda fruticosa has well-established antioxidant, cytoprotective and anti-inflammatory properties. This study evaluated the efficacy of the 80% ethanolic extract of S. fruticosa and its primary phytoconstituents in experimental models of UC. Ethanolic extract of Suaeda fruticosa (SF-Et) prepared by maceration was characterised by quantitative (TPC, TFC, TTC, and TSC) and GC-MS techniques. The nitrite scavenging assay was performed to determine the reactive nitrogen species (RNS) scavenging property. 5% dextran sulfate sodium (DSS, 40KDa Mw) and 3% acetic acid (2 mL) solutions were used to induce UC in rats. Animals were treated with 125, 250, and 500 mg/kg of SF-Et, 500 mg/kg of sulfasalazine, and 10 mg/kg of the compound combination (CC). Physical parameters, such as body weight, stool consistency, and rectal bleeding were examined to determine the severity of UC. Histopathological observations of colon tissues, haematological testing, and qPCR analysis of inflammatory genes were performed to establish the in vivo efficacy of SF-Et. Additionally, the MTT assay was used to evaluate the cytotoxicity of SF-Et and its components against HCT 116 colorectal cancer cells. ADMET predictions for selected compounds were performed using online tools. Quantitative phytochemical screening confirmed the presence of 69.49 ± 6.27 mg GAE/g of TPC, 353.01 ± 8.05 mg QE/g of TFC, 21.7% of TSC, and 34.26 ± 2.02 mg TAE/gram of TTC in SF-Et. GC-MS analysis confirmed the presence of farnesol, n-hexadecanoic acid, and thymol (previous data). Nitrite scavenging activity confirmed the moderate RNS scavenging potential of SF-Et. In DSS and acetic acid-induced colitis models, oral administration of 500 mg/kg of SF-Et and 10 mg/kg of the compound combination significantly mitigated colitis signs, restored haematological parameters, and protected the architecture of colon tissues. qPCR analysis revealed significant (p < 0.05) down-regulation in mRNA expression of inflammatory markers (TNF-α, IL-1β, IL-6, iNOS, COX-2, NF-κB, and PGE2) and up-regulation of the anti-inflammatory cytokine, IL-10, in the SF-Et, CC and SSZ administered groups. Treatment with SF-Et and SSZ produced significant (p < 0.05) elevation in serum GSH and reduction in nitric oxide levels than diseased control group. Moreover, SF-Et and the CC treatment showed dose-dependent cytotoxicity against HCT 116 cells. ADMET prediction showed good intestinal absorption (> 90%) and a relatively low toxicity profile of studied compounds. These findings confirm that S. fruticosa and its major compounds can mitigate UC development by modulating inflammatory and oxidative stress biomarkers.
Indexed as
Identifiers
41718922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.